HIGHLIGHTS
- who: Hironao Okubo and collaborators from the Department of Gastroenterology, Juntendo University Nerima Hospital, Tokyo, Japan have published the Article: Impact of Cabozantinib Exposure on Proteinuria and Muscle Toxicity in Patients with UnresectableHepatocellular Carcinoma, in the Journal: Pharmaceuticals 2022, 15, x FOR PEERkinase REVIEWand of /2022/
- what: The authors aimed to clarify the association between cabozantinib exposure and the development of AEs, including proteinuria and muscle toxicity, in uHCC patients. This study showed that cabozantinib treatment uHCC was associated
SUMMARY
Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.